DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors

• Text
• PDF

Abstract

Effective antitumor T cell activity relies on the expression and MHC presentation of tumor neoantigens. Tumor cells can evade T cell detection by silencing the transcription of antigens or by altering MHC machinery resulting in inadequate neoantigen-specific T cell activation. We identified DNA-PK inhibitor (DNA-PKi) NU7441 as a promising immunomodulator that reduced immunosuppressive proteins while increasing MHC-I expression in a panel of human melanoma cell lines. In tumor-bearing mice, combination therapy using NU7441 and immune adjuvants STING ligand and CD40 agonist (NU-SL40) substantially increased and diversified the neoantigen landscape, antigen presenting machinery, and consequently substantially increased both the number and repertoire of neoantigen-reactive tumor infiltrating lymphocytes (TILs). DNA-PK-inhibition or knockout promoted transcription and protein expression of various neoantigens in human and mouse melanomas and induced sensitivity to ICB in resistant tumors. In patients, PRKDC levels inversely correlated with MHC I expression and CD8 TILs but positively correlated with increased neoantigen loads and improved responses to ICB. These studies suggest that inhibiting DNA-PK activity can restore tumor immunogenicity by increasing neoantigen expression and presentation and broadening the neoantigen-reactive T cell population.

Authors

Allison Joy Nielsen, Gabriella Kyra Albert, Amelia Sanchez, Jiangli Chen, Jing Liu, Andres Sebastian Davalos, Degui Geng, Xander G. Bradeen, Jennifer D. Hintzsche, William Robinson, Martin McCarter, Carol M. Amato, Richard Tobin, Kasey L. Couts, Breelyn Ann Wilky, Eduardo Davila